Dr. Emily Clair McClung, MD

Dr. McClung practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. McClung's NPI, 1851679765, was assigned on July 26, 2011. Dr. McClung graduated from Icahn School Of Medicine At Mount Sinai in 2010. Dr. McClung holds California license A117562.

Dr. McClung's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. McClung's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. McClung is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Stanford Health Care. Dmand AI also links Dr. McClung to 1 more hospital and 1 medical group, each named with a free account. Dr. McClung's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McClung practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. McClung's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. McClung is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. McClung's licenses on file in 3 states: California, Arizona and Florida.

Dmand AI lists hysterectomy, menopause and ovarian cyst among the conditions Dr. McClung treats.

CMS data shows 305 Medicare services from Dr. McClung across 6 procedure codes in 2024, for 136 Medicare patients. Medicare paid $37,985 for them.

CMS counts 136 Medicare patients who saw Dr. McClung in 2024. The largest group is 65 to 74, with 74 patients. 74% of them have high blood pressure, and 74% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McClung's median patient age at 60, with 99% women.

In 2024, Dr. McClung wrote 241 Medicare Part D claims for 59 patients. 71% of them were for generic drugs. CMS names the drug for 101 of them, across 6 drugs with 11 or more claims each, at $23,171 in total drug cost. In 2023, CMS named 66 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. McClung for performance year 2024, reported as part of a group. Dr. McClung accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McClung as offering telehealth. CMS counts 22 procedures of removal of the uterus by Dr. McClung, more than 94% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. McClung, published from 2014 to 2025. 2016 was the busiest year, with 2. The most frequent topics are Endometrial Neoplasms and Gene Expression Regulation, Neoplastic. Dr. McClung has published most often in Gynecol Oncol Rep. Dr. McClung's most frequent co-authors are Robert M. Wenham, MD, Bernadette Mielak Boac, MD and Hye Sook Chon, MD.

Dmand AI links Dr. McClung to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Embryonal, Carcinoma, Endometrioid and Carcinosarcoma.

CMS Open Payments shows 19 general payments to Dr. McClung from 7 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 71% of the total. Ethicon Inc. paid the most, $1,039.

Dr. McClung graduated from Icahn School Of Medicine At Mount Sinai in 2010.

Dr. McClung is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.